CN1233360C - Chinese medicine preparation for treating hemorrhage of the ocular fundus vitreous opacity - Google Patents
Chinese medicine preparation for treating hemorrhage of the ocular fundus vitreous opacity Download PDFInfo
- Publication number
- CN1233360C CN1233360C CN 03104746 CN03104746A CN1233360C CN 1233360 C CN1233360 C CN 1233360C CN 03104746 CN03104746 CN 03104746 CN 03104746 A CN03104746 A CN 03104746A CN 1233360 C CN1233360 C CN 1233360C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine preparation
- radix
- vitreous opacity
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a compound traditional Chinese medicine preparation for treating ophthalmology diseases, particularly to traditional Chinese medicine preparation for treating eyeground hemorrhage and vitreous opacity. The traditional Chinese medicine preparation comprises medicine components of the following proportion by weight percentage: 12.86 to 19.29 of Danshen root, 9.65 to 19.29 of sea-ear shell, 9.65 to 19.29 of cassia occidentalis, 3.22 to 19.29 of nacre, 3.86 to 7.72 of seaweed, 3.86 to 7.72 of laminaria, 1.93 to 6.43 of radix notoginseng powder, 1.93 to 6.43 of cattail pollen, 1.93 to 6.43 of scutellaria, 6.43 to 9.65 of dodder, 3.86 to 9.65 of medicinal cyathula root, 3.22 to 6.43 of atractylodes rhizome. The traditional Chinese medicine preparation can mainly treat new and old vitreous opacity, hematocele, eyeground hemorrhag, exudation, hyphema, and other ophthalmology diseases caused by various reasons, and the total average effective rate of the preparation is as high as 93.25%.
Description
Technical field:
The present invention relates to treat the herbal mixture of ophthalmic diseases, particularly a kind of Chinese medicine preparation for the treatment of the retinal hemorrhage vitreous opacity.
Background technology:
Vitreous hemorrhage, retinal hemorrhage and vitreous opacity belong to commonly encountered diseases, frequently-occurring disease, liquor kalii iodide commonly used clinically at present is oral, be used to promote the absorption of vitreous opacity, merge the hemostasis that Radix Notoginseng Tabellae is used for the hemorrhage phase, the hemorrhage later stage again the compatibility Radix Salviae Miltiorrhizae Tabellae be used for blood circulation promoting and blood stasis dispelling.Though adopt the therapeutic scheme of above all medicines effective, have following drawback:
1, patient's scheme complexity of taking medicine, multiple medicines share and easily causes untoward reaction.Principle of medication clinically is to simplify therapeutic regimen, reduces drug combination as far as possible, avoids or reduce the generation of untoward reaction.
2, potassium iodide oral solution itself has zest, and oral after the gastric acid effect discharges free-iodine, can suppress the effect of digestive enzyme and influences digestion, the patient who has even gastrointestinal reaction takes place.
Summary of the invention:
The purpose of this invention is to provide a kind of complexity that multiple medicines share scheme of taking medicine that both changed, have again effectively, the Chinese medicine preparation of safety, economic traits treatment retinal hemorrhage vitreous opacity.
Its medicine composition of Chinese medicine preparation and the percentage by weight thereof of realizing the foregoing invention purpose are: Radix Salviae Miltiorrhizae 12.86～19.29, Concha Haliotidis, Semen Cassiae each 9.65～19.29, Concha Margaritifera 3.22～19.29, Sargassum, Thallus Laminariae (Thallus Eckloniae) each 3.86～7.72, Radix Notoginseng powder, Pollen Typhae, Radix Scutellariae each 1.93～6.43, Semen Cuscutae 6.43～9.65, Radix Cyathulae 3.86～9.65, Rhizoma Atractylodis 3.22～6.43.The medicine of this Chinese medicine preparation is formed and percentage by weight can also be: Radix Salviae Miltiorrhizae 16.10, Concha Haliotidis, Semen Cassiae each 14.465, Concha Margaritifera 11.25, Sargassum, Thallus Laminariae (Thallus Eckloniae) each 5.785, Radix Notoginseng powder, Pollen Typhae, Radix Scutellariae each 4.18, Semen Cuscutae 8.04, Radix Cyathulae 6.75, Rhizoma Atractylodis 4.82.
The compatibility mechanism of Chinese medicine preparation of the present invention is described as follows:
Modern pharmacological research shows that Radix Salviae Miltiorrhizae has anticoagulation, inhibition and depolymerization platelet aggregation, promotes the effect of humoral immune function; Concha Haliotidis has stronger broad spectrum antibacterial, especially Gram-positive and negative bacteria is had obvious inhibitory action; Semen Cassiae have protect the liver, hepatoprotective, make eye bright, the effect of antiplatelet aggregation, enhancing macrophage phagocytic function; Radix Notoginseng has the effect of obvious hemostasis, anticoagulant and anticoagulant, adjusting immunologic function; Semen Cuscutae helps the adjusting of immunologic function, to protecting transparent crystalline lens, alleviation cataract certain effect is arranged; Sargassum has anticoagulant, anastalsis; Pollen Typhae has the effect of coagulant blood; Thallus Laminariae (Thallus Eckloniae) is used for the vitreous opacity treatment clinically, and is evident in efficacy; The contained flavone of Radix Scutellariae has stronger anticoagulant effect; Concha Margaritifera contains aminoacid such as leucine, methionine, alanine, glycine, glutamic acid, winter propylhomoserin; Radix Cyathulae contains alkaloid; Rhizoma Atractylodis have excited enterokinesia effect, and tubercule bacillus, staphylococcus aureus, large intestine and hay and chlorine pus bacillus are had tangible sterilization functions.
Hemorrhage or the vitreous opacity of the part tissue of eye that the present invention relates to, retina ooze out ophthalmic diseasess such as focus, mostly be that blood vessels retardance, retention of blood stasis, QI and blood are condensed, the many reasons of phlegm and blood stasis, form the tangible thing stasis of blood in ophthalmic, become the deleterious pathological product of a station kind, affect one's power of vision, even cause the destruction of eye inner tissue.Chinese medicine preparation of the present invention is a foundation with above-mentioned modern pharmacological research theory, does not stay the stasis of blood, collateral dredging to make eye bright in line with invigorating blood circulation, stopping blooding and does not hinder positive principle, and in conjunction with whole, side is intended in determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs with local.Radix Salviae Miltiorrhizae, Pollen Typhae, Radix Notoginseng are nourished blood in the side, invigorate blood circulation hemostasis; Concha Haliotidis, Semen Cassiae, Radix Scutellariae heat clearing away, a blood dispels the wind; Sargassum, Thallus Laminariae (Thallus Eckloniae), Concha Margaritifera, Radix Cyathulae, Rhizoma Atractylodis softening the hard mass dampness collateral dredging, the Semen Cuscutae tonifying kidney and improving eyesight, all medicines are played the merit of promoting blood circulation to remove obstruction in the collateral, liver heat removing and eyesight improving altogether.Therefore, Chinese medicine preparation of the present invention can cure mainly fresh and old vitreous opacity, hematocele, retinal hemorrhage due to a variety of causes, ooze out, ophthalmic diseases such as hyphema.
By prescription of the present invention, this Chinese medicine preparation can pass through conventional Chinese medicine reparation technology, makes powder or granule.Usage: take after mixing it with water.Consumption: each 10g, every day 3 times, 12 days is a course of treatment.Therapeutic scheme: the fresh hemorrhage and fresh vitreous in optical fundus is muddy to need 4-5 course of treatment of continuous oral, optical fundus remote hemorrhage person is further consultation in time after taking 4-5 the course of treatment, just send out the vitreous opacity patient and take the 4-5 course of treatment continuously, outmoded vitreous opacity merges the person of organising and takes 8-9 the course of treatment continuously, and further consultation at any time.
Model case:
Case 1: woman, 67 years old, the main suit: muscae genetic vision waved for 2 weeks, through looking into: V=0.8, left eye prosthomere (-), the optical fundus: optic disc border C/O=0.2, color is light red, nethike embrane A:V=1: 3, A, V intersection is levied (+), the macular area pigment is slightly disorderly, central fovea luminous reflectance (+), B ultrasonic: see the cotton-shaped dark hypoecho luminous point of point-like in the vitreous body.Diagnosis: fresh vitreous muddiness.Treatment: take this Chinese medicine preparation granule continuously after 4-5 course of treatment, main suit's shadow disappears, and examination of eyes is the same, B ultrasonic: show that the interior cotton-shaped echo of point-like of vitreous body obviously reduces.
Case 2: the man, 39 years old, main cause right eye firecracker be wound, and visual deterioration is examined over the past half year.Through looking into: V=0.03, can not correct, cornea of right eye is transparent, and dark among the anterior chamber, iris texture is owed clearly, and pupil 4 * 3mm is not round.B ultrasonic: a large amount of strong echoes of vitreous chamber are streak, lumps.Diagnosis: old vitreous opacity.Treatment: take this Chinese medicine preparation granule continuously after 8-9 course of treatment, through having a medical check-up: V:0.06, correct: V:0.12, anterior ocular segment is the same, vitreous opacity obviously alleviates, bar Suo Mingxian reduces, big of optical fundus as seen, the optic disc border is clear, color is light red, that nethike embrane is not seen is obviously hemorrhage, ooze out, the disorder of macular area pigment, and the central fovea luminous reflectance is not seen.B ultrasonic: vitreous body agglomerate sample, streak echo obviously die down, reduce.
Case 3: the man, 35 years old, main cause right eye wooden unit wounded, and visual deterioration was examined over 1 day.Through looking into: V=0.05, upper and lower eyelid are purple clearly, the hyperemia of bulbar conjunctiva Combination, below bulbar conjunctiva laceration 5mm, cornea is flaggy laceration 3mm in length and breadth, pupil diameter 3mm, and behind the medicine mydriasis, crystal is transparent, the inhomogeneous muddiness of vitreous body, remarkable hematocele, and see a large amount of canescence micronic dust shape granules, the optical fundus is peeped unclear.B ultrasonic: vitreous chamber agglomerate sample echo, part links to each other with nethike embrane.Diagnosis: fresh vitreous is hemorrhage.Treatment: take this Chinese medicine preparation granule continuously after 4-5 course of treatment, through having a medical check-up: V:0.5 can not correct, the hematopsia absorption, crystal is transparent, and vitreous body is left over part canescence machine bar rope, and the optic disc border is clear, color is light red, and that nethike embrane is not seen is hemorrhage, ooze out macular area central fovea luminous reflectance (+).
Case 4: the man, 47 years old, main cause right eye reinforcing bar was stabbed, and visual deterioration was examined over 4 months.Through looking into: V=0.02, can not correct, right eye below limbus of corneae is seen the about 5mm of abnormal pigmentary deposit on the skin trace, lacked in 1/3 week under the iris as, crystal lack as, see hematocele in the vitreous body, be kermesinus and canescence machine bar rope, the optical fundus only optic disc as seen, color is light red, C/O=0.1, surplus peep unclear.Diagnosis: old vitreous hemorrhage.Treatment: take this Chinese medicine preparation granule continuously after 8-9 course of treatment, through having a medical check-up: V:0.08, correct: V:0.3, the right eye prosthomere is the same, and intravitreal blood absorbs, and leaves over a small amount of canescence machine bar rope, the optical fundus as seen, the optic disc border is clear, and that nethike embrane is not seen is hemorrhage, ooze out, and the recessed luminous reflectance of macular area is latent to be seen.
Observation of curative effect: clinical observation on the therapeutic effect such as the table 1 of the applicant by over nearly 3 years 1000 routine patients of indication under this Chinese medicine preparation being carried out.
Table 1
| Group | The eye number | Recovery from illness | Produce effects | Invalid | Total effective rate % |
| Optical fundus fresh hemorrhage (in 10 days) | 417 | ?351 | ?56 | ?10 | ?97.60 |
| Optical fundus outmoded hemorrhage (after 10 days) | 213 | ?71 | ?130 | ?12 | ?94.37 |
| The fresh vitreous muddiness | 242 | ?103 | ?129 | ?10 | ?95.87 |
| Outmoded vitreous opacity | 128 | ?16 | ?93 | ?19 | ?85.15 |
| Add up to | 1000 |
Hemorrhage and vitreous opacity has obvious curative effects, total effective rate average out to 93.25% to ocular tissue for data declaration in the table, Chinese medicine preparation of the present invention.Observation on Clinical Application through 1000 many cases proves that this Chinese medicine preparation does not have any poison and pays effect simultaneously.
The specific embodiment:
Below provide 5 specific embodiments of the present invention and see Table 2.
Press and give concrete prescription in the table 2, weigh the Chinese medicine of respectively distinguishing the flavor of, Chinese medicine reparation technology is routinely made granule then.Technological requirement:, should choose high-quality raw material of Chinese medicine for guaranteeing the curative effect of finished medicines; For guaranteeing effective extraction of volatile substance, use the totally-enclosed extraction of multi-functional extraction concentration tank; For guaranteeing that the thermal sensitivity effective ingredient is not destroyed, vacuum and low temperature to concentrate to shorten concentration time; For guaranteeing the seriality of technical process, guarantee drug effect, in the ethanol removal process, adopt the reverse-flow type of cryogenic vacuum; For guaranteeing particulate quality, preferably use the infinitely variable speeds oscillating granulator.
Table 2
| Material name | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | |||||
| Weight g | Content % | Weight g | Content % | Weight g | Content % | Weight g | Content % | Weight g | Content % | |
| Radix Salviae Miltiorrhizae | 25 | ?16.10 | ?20 | ?12.86 | ?30 | ?19.29 | ?30 | ?19.29 | ?22.5 | ?14.465 |
| Concha Haliotidis | 22.5 | ?14.465 | ?30 | ?19.29 | ?15 | ?9.65 | ?28 | ?18.01 | ?21 | ?13.505 |
| Semen Cassiae | 22.5 | ?14.465 | ?15 | ?9.65 | ?30 | ?19.29 | ?28 | ?18.01 | ?21 | ?13.505 |
| Concha Margaritifera | 17.5 | ?11.25 | ?10 | ?6.43 | ?11.5 | ?7.38 | ?5 | ?3.22 | ?30 | ?19.29 |
| Sargassum | 9 | ?5.785 | ?6 | ?3.86 | ?12 | ?7.72 | ?9 | ?5.785 | ?9 | ?5.785 |
| Thallus Laminariae (Thallus Eckloniae) | 9 | ?5.785 | ?12 | ?7.72 | ?6 | ?3.86 | ?9 | ?5.785 | ?9 | ?5.785 |
| Radix Notoginseng powder | 6.5 | ?4.18 | ?9 | ?5.785 | ?3 | ?1.93 | ?10 | ?6.43 | ?5 | ?3.22 |
| Pollen Typhae | 6.5 | ?4.18 | ?9 | ?5.785 | ?10 | ?6.43 | ?3 | ?1.93 | ?5 | ?3.22 |
| Radix Scutellariae | 6.5 | ?4.18 | ?9 | ?5.785 | ?3 | ?1.93 | ?10 | ?6.43 | ?5 | ?3.22 |
| Semen Cuscutae | 12.5 | ?8.04 | ?10.5 | ?6.755 | ?15 | ?9.65 | ?10 | ?6.43 | ?12.5 | ?8.04 |
| Radix Cyathulae | 10.5 | ?6.75 | ?15 | ?9.65 | ?15 | ?9.65 | ?6 | ?3.86 | ?8 | ?5.145 |
| Rhizoma Atractylodis | 7.5 | ?4.82 | ?10 | ?6.43 | ?5 | ?3.22 | ?7.5 | ?4.82 | ?7.5 | ?4.82 |
| Add up to | 155.5 | ?100 | ?155.5 | ?100 | ?155.5 | ?100 | ?155.5 | ?100 | ?155.5 | ?100 |
Claims (2)
1, a kind of Chinese medicine preparation for the treatment of the retinal hemorrhage vitreous opacity, the medicine composition and the percentage by weight thereof that it is characterized in that said preparation are: Radix Salviae Miltiorrhizae 12.86～19.29, Concha Haliotidis, Semen Cassiae each 9.65～19.29, Concha Margaritifera 3.22～19.29, Sargassum, Thallus Laminariae (Thallus Eckloniae) each 3.86～7.72, Radix Notoginseng powder, Pollen Typhae, Radix Scutellariae each 1.93～6.43, Semen Cuscutae 6.43～9.65, Radix Cyathulae 3.86～9.65, Rhizoma Atractylodis 3.22～6.43.
2, the Chinese medicine preparation of treatment retinal hemorrhage vitreous opacity according to claim 1, the medicine composition and the percentage by weight thereof that it is characterized in that said preparation are: Radix Salviae Miltiorrhizae 16.10, Concha Haliotidis, Semen Cassiae each 14.465, Concha Margaritifera 11.25, Sargassum, Thallus Laminariae (Thallus Eckloniae) each 5.785, Radix Notoginseng powder, Pollen Typhae, Radix Scutellariae each 4.18, Semen Cuscutae 8.04, Radix Cyathulae 6.75, Rhizoma Atractylodis 4.82.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03104746 CN1233360C (en) | 2003-02-28 | 2003-02-28 | Chinese medicine preparation for treating hemorrhage of the ocular fundus vitreous opacity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03104746 CN1233360C (en) | 2003-02-28 | 2003-02-28 | Chinese medicine preparation for treating hemorrhage of the ocular fundus vitreous opacity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1524539A CN1524539A (en) | 2004-09-01 |
| CN1233360C true CN1233360C (en) | 2005-12-28 |
Family
ID=34282351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03104746 Expired - Fee Related CN1233360C (en) | 2003-02-28 | 2003-02-28 | Chinese medicine preparation for treating hemorrhage of the ocular fundus vitreous opacity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1233360C (en) |
-
2003
- 2003-02-28 CN CN 03104746 patent/CN1233360C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1524539A (en) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100553657C (en) | A kind of Chinese medicine composition of orally taken for curing cataract | |
| CN101648018A (en) | Medicinal composition for treating ophthalmic inflammation and application thereof | |
| CN103083546B (en) | Method for processing condensed pill for regaining sight | |
| CN103585363A (en) | Traditional Chinese medicine composition for treating senile cataract | |
| CN113413415B (en) | Lanosterol eye drops and preparation method thereof | |
| CN1160091C (en) | Medicine for treating ophthalmopathy | |
| CN1233360C (en) | Chinese medicine preparation for treating hemorrhage of the ocular fundus vitreous opacity | |
| CN1127960C (en) | Eyesight improving medicine liquid | |
| CN102755549B (en) | Drug for curing cataract and preparation method thereof | |
| CN1256128C (en) | Eye disease treating medicine | |
| CN103405609B (en) | Traditional Chinese medicine preparation for treating cataract | |
| CN100423731C (en) | Eye brightening eye washing liquid and its preparation method | |
| CN1400004A (en) | Chinese medicine preparation for curing chronic conjunctivitis | |
| CN101869631B (en) | Toxicant elimination medicament for eyes | |
| CN101181433A (en) | Chinese medicine medicament for curing pterygium | |
| CN105726983A (en) | Compound dendrobium eye drops for treating xerophthalmia and preparation method thereof | |
| CN1268354C (en) | Traditional Chinese medicine preparation for treating myopia and method for preparing the same | |
| CN102274242B (en) | Traditional Chinese medicine formula for treating eye disease and manufacturing method thereof | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN105250394A (en) | Traditional Chinese medicine composition for treating cataract and preparation method and application thereof | |
| CN106581221A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN106491730A (en) | A kind of treat Chinese medicine composition of glaucoma and preparation method thereof | |
| CN102641431B (en) | Medicament for treating vitreous opacity | |
| CN105125848A (en) | Traditional Chinese medicine for treating dry eye syndromes | |
| CN102151312B (en) | Medicament for treating vitreous hematocele and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |